- Last edited on February 9, 2024
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Previous revision | ||
|
geri:dementia:alzheimers [on June 2, 2019] |
geri:dementia:alzheimers [on April 13, 2020] |
||
|---|---|---|---|
| Line 106: | Line 106: | ||
| ===== Investigations ===== | ===== Investigations ===== | ||
| - | The diagnosis of Alzheimer's Disease remains a clinical diagnosis, though neuroimaging and biomarkers are beginning to play a larger role in diagnosis. Amyloid-based diagnostic tests such as amyloid imaging on brain positron emission tomography (PET) scans and measuring amyloid beta-42 (look for reduced levels) in the [[neurology:investigations:lp|cerebrospinal fluid]] (CSF) may sometimes be helpful. Signs of neuronal injury, such as hippocampal and temporoparietal cortical atrophy on a MRI or temporoparietal hypometabolism on a fluorodeoxyglucose PET scan may provide non-specific evidence for AD. | + | The diagnosis of Alzheimer's Disease remains a clinical diagnosis, though neuroimaging and biomarkers are beginning to play a larger role in diagnosis. Amyloid-based diagnostic tests such as amyloid imaging on brain positron emission tomography (PET) scans and measuring amyloid beta-42 (look for reduced levels) in the [[neurology:lumbar-puncture-lp|cerebrospinal fluid]] (CSF) may sometimes be helpful. Signs of neuronal injury, such as hippocampal and temporoparietal cortical atrophy on a MRI or temporoparietal hypometabolism on a fluorodeoxyglucose PET scan may provide non-specific evidence for AD. |
| ===== Treatment ===== | ===== Treatment ===== | ||
| Current treatments do not alter the course of the disease. Medications only serve to reduce the rate of decline, and symptomatic improvement. | Current treatments do not alter the course of the disease. Medications only serve to reduce the rate of decline, and symptomatic improvement. | ||